MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

FOXC1

  • Home
  • FOXC1
Association of FOXC1 Duplications With Juvenile Open-Angle Glaucoma
Posted innews Ophthalmology

Association of FOXC1 Duplications With Juvenile Open-Angle Glaucoma

Posted by By MedXY 05/13/2026
A multicenter study found FOXC1 duplications in multiple glaucoma families, strongly linked to juvenile open-angle glaucoma with high penetrance and variable eye and subtle systemic features, supporting routine copy-number testing in selected patients.
Read More
Metronomic Capecitabine Gives Durable 10‑Year DFS Benefit in Early Triple‑Negative Breast Cancer — FOXC1 May Identify Who Benefits
Posted innews Oncology

Metronomic Capecitabine Gives Durable 10‑Year DFS Benefit in Early Triple‑Negative Breast Cancer — FOXC1 May Identify Who Benefits

Posted by By MedXY 11/30/2025
A 10‑year follow‑up of SYSUCC‑001 shows 1 year of metronomic capecitabine after standard adjuvant therapy improved disease‑free survival in early triple‑negative breast cancer; FOXC1 expression emerged as a potential predictive biomarker in exploratory analyses.
Read More
  • Deep Learning on CT Scans Enhances Prognostication of Interstitial Lung Abnormalities
  • Ocular Metastasis Over Four Decades: Clinical Patterns, Survival, and Therapeutic Outcomes in 569 Patients
  • HPV Positivity in Keratinizing Nasopharyngeal Carcinoma: Implications for Prognosis and Clinical Practice
  • Impact of Patient-Level Social Determinants on Colon Cancer Outcomes: A Novel Prognostic Measure Within an Integrated Health Network
  • Adjunctive Metformin with Progestin in Fertility-Sparing Treatment of Endometrial Neoplasia: Insights from the FELICIA Trial
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation ischemic stroke MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top